# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0001193125-26-204161
**Filing Date:** 2026-5
**Character Count:** 16190
**Document Hash:** 063d9249279633c1fc0db94cbf6af3d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-204161.hdr.sgml**: 20260504

**ACCESSION NUMBER**: 0001193125-26-204161

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 134

**CONFORMED PERIOD OF REPORT**: 20260504

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260504

**DATE AS OF CHANGE**: 20260504

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Perspective Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411458152
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 26938521

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-676-0900

**MAIL ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Isoray, Inc.
- **DATE OF NAME CHANGE:** 20181231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 04, 2026<br>

------

Perspective Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33407 | 41-1458152 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| c/o Perspective Therapeutics, Inc.<br>2401 Elliott Avenue<br>Suite 320 |  |  |
| Seattle**,** Washington |  | 98121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (206) 676-0900<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CATX | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 2.02 Results of Operations and Financial Condition.

## On May 4, 2026, Perspective Therapeutics, Inc. (the "Company") posted to its website a presentation (the "Presentation") containing slides presented at an analyst event hosted by the Company on that date and certain other slides regarding the Company's clinical programs and manufacturing technologies and infrastructure. The Presentation contains certain estimated and projected financial information, including the Company's estimated cash, cash equivalents and short-term investments as of March 31, 2026. The estimated and projected financial information included in the Presentation is preliminary and has not been audited, reviewed or compiled by the Company's independent registered public accounting firm, WithumSmith+Brown, PC ("Withum"), and Withum has not completed its procedures with respect to the preliminary financial data. Accordingly, Withum does not express an opinion or any other form of assurance with respect thereto.
The Company's actual results as of March 31, 2026 may differ from the preliminary financial data due to the completion of the Company's closing procedures with respect to the quarter ended March 31, 2026, final adjustments and other developments that may arise between now and the time the financial results for the such fiscal quarter are finalized.

## Item 8.01 Other Events.
On May 4, 2026, the Company posted the Presentation to its website. A copy of the Presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [<u>Company Presentation</u>](catx-ex99_1.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PERSPECTIVE THERAPEUTICS, INC.** |
| Date: | May 4, 2026 | By:  | /s/ Joel Sendek |
|  |  |  | Joel Sendek<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![Slide 1](catx-ex99_1s1.jpg)

------

![Slide 2](catx-ex99_1s2.jpg)

------

![Slide 3](catx-ex99_1s3.jpg)

Agenda

------

![Slide 4](catx-ex99_1s4.jpg)

------

![Slide 5](catx-ex99_1s5.jpg)

Engineering the Alpha Advantage in Targeted Oncology

------

![Slide 6](catx-ex99_1s6.jpg)

Optimizing the Entire System

------

![Slide 7](catx-ex99_1s7.jpg)

Expanding the Addressable Market

------

![Slide 8](catx-ex99_1s8.jpg)

Unlocking New Treatment Options Across Solid Tumors:

------

![Slide 9](catx-ex99_1s9.jpg)

Choosing The Right Isotope

------

![Slide 10](catx-ex99_1s10.jpg)

Optimizing Structural Chemistry:

------

![Slide 11](catx-ex99_1s11.jpg)

Not All ²¹²Pb Programs Are Created Equal

------

![Slide 12](catx-ex99_1s12.jpg)

Advancing a Theranostic Approach:

------

![Slide 13](catx-ex99_1s13.jpg)

A Decade of Deliberate, End-to-End Engineering

------

![Slide 14](catx-ex99_1s14.jpg)

Direct-to-Hospital Delivery through Integrated Isotope Production

------

![Slide 15](catx-ex99_1s15.jpg)

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

------

![Slide 16](catx-ex99_1s16.jpg)

Reaching the Largest Addressable Market with Regional Manufacturing

------

![Slide 17](catx-ex99_1s17.jpg)

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

------

![Slide 18](catx-ex99_1s18.jpg)

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

------

![Slide 19](catx-ex99_1s19.jpg)

------

![Slide 20](catx-ex99_1s20.jpg)

Perspective Therapeutics

------

![Slide 21](catx-ex99_1s21.jpg)

------

![Slide 22](catx-ex99_1s22.jpg)

Theranostics in management of patients with neuroendocrine and other SSTR positive tumors

------

![Slide 23](catx-ex99_1s23.jpg)

Objectives

------

![Slide 24](catx-ex99_1s24.jpg)

Treatment landscape

------

![Slide 25](catx-ex99_1s25.jpg)

Adverse side effects

------

![Slide 26](catx-ex99_1s26.jpg)

Other factors that drive treatment

------

![Slide 27](catx-ex99_1s27.jpg)

Survival expectations

------

![Slide 28](catx-ex99_1s28.jpg)

NCCN guidelines

------

![Slide 29](catx-ex99_1s29.jpg)

Treatment decision making

------

![Slide 30](catx-ex99_1s30.jpg)

Alpha particle PRRT

------

![Slide 31](catx-ex99_1s31.jpg)

The evolution of the treatment continuum

------

![Slide 32](catx-ex99_1s32.jpg)

Summary

------

![Slide 33](catx-ex99_1s33.jpg)

------

![Slide 34](catx-ex99_1s34.jpg)

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

------

![Slide 35](catx-ex99_1s35.jpg)

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

------

![Slide 36](catx-ex99_1s36.jpg)

------

![Slide 37](catx-ex99_1s37.jpg)

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

------

![Slide 38](catx-ex99_1s38.jpg)

VMT-⍺-NET: Baseline Patient Characteristics in AACR 2026 Data Analysis

------

![Slide 39](catx-ex99_1s39.jpg)

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in AACR 2026 Data Analysis

------

![Slide 40](catx-ex99_1s40.jpg)

------

![Slide 41](catx-ex99_1s41.jpg)

Blood Creatinine During Follow-up for All Patients Treated (n=64)

------

![Slide 42](catx-ex99_1s42.jpg)

VMT-⍺-NET: Durable Disease Control Across All Doses

------

![Slide 43](catx-ex99_1s43.jpg)

Spider plot of tumor change over time by patient

------

![Slide 44](catx-ex99_1s44.jpg)

VMT-α-NET Responses Deepen Over Time

------

![Slide 45](catx-ex99_1s45.jpg)

VMT-α-NET's Compelling Profile Supports Potential Registration Study at Current Dose Level

------

![Slide 46](catx-ex99_1s46.jpg)

Why Frontloading?

------

![Slide 47](catx-ex99_1s47.jpg)

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

------

![Slide 48](catx-ex99_1s48.jpg)

Meningioma

------

![Slide 49](catx-ex99_1s49.jpg)

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

------

![Slide 50](catx-ex99_1s50.jpg)

------

![Slide 51](catx-ex99_1s51.jpg)

------

![Slide 52](catx-ex99_1s52.jpg)

[212Pb]Pb-VMT--NET after previous radio-ligand treatment

------

![Slide 53](catx-ex99_1s53.jpg)

Dresden VMT--NET compassionate use program

------

![Slide 54](catx-ex99_1s54.jpg)

Dresden VMT--NET compassionate use program

------

![Slide 55](catx-ex99_1s55.jpg)

Dresden VMT--NET compassionate use program

------

![Slide 56](catx-ex99_1s56.jpg)

Dresden VMT--NET compassionate use program

------

![Slide 57](catx-ex99_1s57.jpg)

First results - compassionate use program

------

![Slide 58](catx-ex99_1s58.jpg)

First results - compassionate use program

------

![Slide 59](catx-ex99_1s59.jpg)

First results - compassionate use program

------

![Slide 60](catx-ex99_1s60.jpg)

First results - compassionate use program

------

![Slide 61](catx-ex99_1s61.jpg)

------

![Slide 62](catx-ex99_1s62.jpg)

First results - compassionate use program

------

![Slide 63](catx-ex99_1s63.jpg)

First results - compassionate use program

------

![Slide 64](catx-ex99_1s64.jpg)

Case Study

------

![Slide 65](catx-ex99_1s65.jpg)

Case Study

------

![Slide 66](catx-ex99_1s66.jpg)

Case Study

------

![Slide 67](catx-ex99_1s67.jpg)

Case Study

------

![Slide 68](catx-ex99_1s68.jpg)

Imaging and dosimetry

------

![Slide 69](catx-ex99_1s69.jpg)

Conclusion

------

![Slide 70](catx-ex99_1s70.jpg)

------

![Slide 71](catx-ex99_1s71.jpg)

------

![Slide 72](catx-ex99_1s72.jpg)

How biodistribution informs therapeutic potential

------

![Slide 73](catx-ex99_1s73.jpg)

Disclosures

------

![Slide 74](catx-ex99_1s74.jpg)

------

![Slide 75](catx-ex99_1s75.jpg)

PSMA vs DOTATATE

------

![Slide 76](catx-ex99_1s76.jpg)

PSMA vs DOTATATE

------

![Slide 77](catx-ex99_1s77.jpg)

PSMA vs DOTATATE

------

![Slide 78](catx-ex99_1s78.jpg)

Patient's journey from PSA>MRI>PSMA PET

------

![Slide 79](catx-ex99_1s79.jpg)

Receptor Targeted PET enabled a fundamentally different clinical trial design: Treat if you see it

------

![Slide 80](catx-ex99_1s80.jpg)

68Ga/177Lu-PSMASuper vs Non-Responder

------

![Slide 81](catx-ex99_1s81.jpg)

68Ga/177Lu-DOTATATESuper vs Non-Responder

------

![Slide 82](catx-ex99_1s82.jpg)

Radioligand Therapy Today"Science advances one funeral at a time" Max Planck

------

![Slide 83](catx-ex99_1s83.jpg)

Radioligand Therapy Today"Science advances one funeral at a time" Max Planck

------

![Slide 84](catx-ex99_1s84.jpg)

FAP is an Emerging Target

------

![Slide 85](catx-ex99_1s85.jpg)

Not every FAP is bio-identical

------

![Slide 86](catx-ex99_1s86.jpg)

TheranosticsShort Half-lives for Long, Full Lives

------

![Slide 87](catx-ex99_1s87.jpg)

FIH 203/212Pb Pb-VMT-α-NET Perspective Therapeutics

------

![Slide 88](catx-ex99_1s88.jpg)

FIH 203/212Pb Pb-VMT-α-NET Perspective Therapeutics

------

![Slide 89](catx-ex99_1s89.jpg)

Early, Medium and Late Biodistribution Should Inform Therapeutic Window

------

![Slide 90](catx-ex99_1s90.jpg)

Perspective's CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa

------

![Slide 91](catx-ex99_1s91.jpg)

Development of PSV594 for CCK2R+ Tumor types

------

![Slide 92](catx-ex99_1s92.jpg)

CCK2R: Implicated in Multiple Tumor Types With Major Unmet Needs

------

![Slide 93](catx-ex99_1s93.jpg)

------

![Slide 94](catx-ex99_1s94.jpg)

------

![Slide 95](catx-ex99_1s95.jpg)

Expanding the Addressable Market

------

![Slide 96](catx-ex99_1s96.jpg)

Optimizing the Entire System

------

![Slide 97](catx-ex99_1s97.jpg)

A Decade of Deliberate, End-to-End Engineering

------

![Slide 98](catx-ex99_1s98.jpg)

Built Over a Decade:

------

![Slide 99](catx-ex99_1s99.jpg)

Q&A

------

![Slide 100](catx-ex99_1s100.jpg)

Advancing a Theranostic Approach:

------

![Slide 101](catx-ex99_1s101.jpg)

212Pb is Our Isotope of Choice

------

![Slide 102](catx-ex99_1s102.jpg)

Choosing The Right Isotope

------

![Slide 103](catx-ex99_1s103.jpg)

Kinetics Matter: 212Pb Hits Hard and Fast For Strong Activity with Less Systemic Exposure

------

![Slide 104](catx-ex99_1s104.jpg)

𝜶-Particles Delivers More Potent, Targeted Tumor Killing vs. β-Particles

------

![Slide 105](catx-ex99_1s105.jpg)

212Pb Further Enhanced by Proprietary Chelator for Targeted Delivery of Payload

------

![Slide 106](catx-ex99_1s106.jpg)

212Pb Multi-Mechanistic Activity Drives Tumor Destruction and Anti-Tumor Immunity

------

![Slide 107](catx-ex99_1s107.jpg)

Rationale for Synergy with Immune Checkpoint Inhibitors

------

![Slide 108](catx-ex99_1s108.jpg)

212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors

------

![Slide 109](catx-ex99_1s109.jpg)

212Pb Half-life Is More Convenient for Customers

------

![Slide 110](catx-ex99_1s110.jpg)

------

![Slide 111](catx-ex99_1s111.jpg)

------

![Slide 112](catx-ex99_1s112.jpg)

------

![Slide 113](catx-ex99_1s113.jpg)

Advancing a Theranostic Approach:

------

![Slide 114](catx-ex99_1s114.jpg)

Supply Chain and Manufacturing Infrastructure

------

![Slide 115](catx-ex99_1s115.jpg)

End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway

------

![Slide 116](catx-ex99_1s116.jpg)

Direct-to-Hospital Delivery through Integrated Isotope Production

------

![Slide 117](catx-ex99_1s117.jpg)

Reliable, On-Demand 212Pb from 228Th and 224Ra

------

![Slide 118](catx-ex99_1s118.jpg)

Flexible Scalable 224Ra Supply Enables Regional Manufacturing

------

![Slide 119](catx-ex99_1s119.jpg)

Ideal for Regional Manufacturing

------

![Slide 120](catx-ex99_1s120.jpg)

On-Demand Fulfillment at Regional Sites for Finished Product Delivery

------

![Slide 121](catx-ex99_1s121.jpg)

Daily Production at Regional Sites Ensures Supply of Ready-to-administer Product

------

![Slide 122](catx-ex99_1s122.jpg)

Reaching the Largest Addressable Market with Regional Manufacturing

------

![Slide 123](catx-ex99_1s123.jpg)

Mature, Well-Established Distribution Networks

------

![Slide 124](catx-ex99_1s124.jpg)

Network Approach Chosen by Novartis